S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Global shares trade mixed following technology selloff on Wall Street
What is a Growth Stock Mutual Fund?
New "Mined in America" Lithium Opportunities? (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
New "Mined in America" Lithium Opportunities? (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Global shares trade mixed following technology selloff on Wall Street
What is a Growth Stock Mutual Fund?
New "Mined in America" Lithium Opportunities? (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
New "Mined in America" Lithium Opportunities? (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Global shares trade mixed following technology selloff on Wall Street
What is a Growth Stock Mutual Fund?
New "Mined in America" Lithium Opportunities? (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
New "Mined in America" Lithium Opportunities? (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Global shares trade mixed following technology selloff on Wall Street
What is a Growth Stock Mutual Fund?
New "Mined in America" Lithium Opportunities? (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
New "Mined in America" Lithium Opportunities? (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
NASDAQ:HOWL

Werewolf Therapeutics (HOWL) Stock Forecast, Price & News

$3.38
-0.09 (-2.59%)
(As of 06/7/2023 ET)
Compare
Today's Range
$3.38
$3.67
50-Day Range
$2.31
$3.65
52-Week Range
$1.39
$7.51
Volume
46,930 shs
Average Volume
35,227 shs
Market Capitalization
$120.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.10

Werewolf Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
228.4% Upside
$11.10 Price Target
Short Interest
Healthy
0.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.46mentions of Werewolf Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.32) to ($1.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

349th out of 981 stocks

Pharmaceutical Preparations Industry

163rd out of 485 stocks


HOWL stock logo

About Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOWL Stock News Headlines

New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Werewolf Therapeutics (NASDAQ:HOWL) PT Raised to $10.00
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Expert Ratings for Werewolf Therapeutics
Analyst Ratings for Werewolf Therapeutics
Werewolf Therapeutics (NASDAQ:HOWL) PT Lowered to $15.00
See More Headlines

HOWL Price History

HOWL Company Calendar

Last Earnings
3/23/2023
Today
6/07/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HOWL
Fax
N/A
Employees
46
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.10
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$8.30
Forecasted Upside/Downside
+228.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-53,810,000.00
Net Margins
-241.79%
Pretax Margin
-241.79%

Debt

Sales & Book Value

Annual Sales
$16.40 million
Book Value
$3.98 per share

Miscellaneous

Free Float
13,283,000
Market Cap
$120.36 million
Optionable
Not Optionable
Beta
0.20

Key Executives

  • Dr. Daniel J. Hicklin Ph.D. (Age 59)
    Founder, CEO, Pres, Sec. & Director
    Comp: $817.31k
  • Dr. Cynthia Seidel-Dugan Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $600.35k
  • Dr. Randi Isaacs M.D. (Age 67)
    Chief Medical Officer
    Comp: $637.15k
  • Mr. Timothy W. Trost CPA (Age 65)
    CFO, Treasurer & Assistant Sec.
  • Dr. Reid Leonard Ph.D. (Age 64)
    Chief Operating Officer
  • Dr. Chulani Karunatilake Ph.D. (Age 64)
    Chief Technology Officer
  • Ms. Ellen A. Lubman M.B.A. (Age 47)
    Chief Bus. Officer













HOWL Stock - Frequently Asked Questions

Should I buy or sell Werewolf Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HOWL shares.
View HOWL analyst ratings
or view top-rated stocks.

What is Werewolf Therapeutics' stock price forecast for 2023?

2 brokers have issued 1 year target prices for Werewolf Therapeutics' shares. Their HOWL share price forecasts range from $8.30 to $15.00. On average, they predict the company's stock price to reach $11.10 in the next twelve months. This suggests a possible upside of 228.4% from the stock's current price.
View analysts price targets for HOWL
or view top-rated stocks among Wall Street analysts.

How have HOWL shares performed in 2023?

Werewolf Therapeutics' stock was trading at $2.05 on January 1st, 2023. Since then, HOWL stock has increased by 64.9% and is now trading at $3.38.
View the best growth stocks for 2023 here
.

When is Werewolf Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our HOWL earnings forecast
.

How were Werewolf Therapeutics' earnings last quarter?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) released its earnings results on Thursday, March, 23rd. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.20. The firm had revenue of $7.28 million for the quarter, compared to analyst estimates of $3.15 million. Werewolf Therapeutics had a negative net margin of 241.79% and a negative trailing twelve-month return on equity of 40.02%.

When did Werewolf Therapeutics IPO?

(HOWL) raised $101 million in an initial public offering (IPO) on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Werewolf Therapeutics' stock symbol?

Werewolf Therapeutics trades on the NASDAQ under the ticker symbol "HOWL."

Who are Werewolf Therapeutics' major shareholders?

Werewolf Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rubric Capital Management LP (5.45%), Alyeska Investment Group L.P. (1.12%), Acadian Asset Management LLC (0.22%), Schonfeld Strategic Advisors LLC (0.21%), HBK Sorce Advisory LLC (0.15%) and State Street Corp (0.14%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard.
View institutional ownership trends
.

How do I buy shares of Werewolf Therapeutics?

Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Werewolf Therapeutics' stock price today?

One share of HOWL stock can currently be purchased for approximately $3.38.

How much money does Werewolf Therapeutics make?

Werewolf Therapeutics (NASDAQ:HOWL) has a market capitalization of $120.36 million and generates $16.40 million in revenue each year. The company earns $-53,810,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

How can I contact Werewolf Therapeutics?

Werewolf Therapeutics' mailing address is 1030 MASSACHUSETTS AVENUE SUITE 210, CAMBRIDGE MA, 02138. The official website for the company is werewolftx.com. The company can be reached via phone at 617-952-0555 or via email at ir@werewolftx.com.

This page (NASDAQ:HOWL) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -